BR112018074299A2 - composições farmacêuticas compreendendo eteplirsen - Google Patents

composições farmacêuticas compreendendo eteplirsen

Info

Publication number
BR112018074299A2
BR112018074299A2 BR112018074299-6A BR112018074299A BR112018074299A2 BR 112018074299 A2 BR112018074299 A2 BR 112018074299A2 BR 112018074299 A BR112018074299 A BR 112018074299A BR 112018074299 A2 BR112018074299 A2 BR 112018074299A2
Authority
BR
Brazil
Prior art keywords
eteplirsen
pharmaceutical compositions
subject
administering
treating
Prior art date
Application number
BR112018074299-6A
Other languages
English (en)
Inventor
Holt Thomas
Original Assignee
Sarepta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics, Inc. filed Critical Sarepta Therapeutics, Inc.
Publication of BR112018074299A2 publication Critical patent/BR112018074299A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

são fornecidas aqui composições farmacêuticas compreendendo eteplirsen. também são fornecidos aqui métodos de tratamento de uma doença muscular em um indivíduo com necessidade do mesmo, compreendendo administrar ao indivíduo uma composição farmacêutica da divulgação.
BR112018074299-6A 2016-05-24 2017-05-24 composições farmacêuticas compreendendo eteplirsen BR112018074299A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US62/340,947 2016-05-24
US201662429160P 2016-12-02 2016-12-02
US62/429,160 2016-12-02
PCT/US2017/034265 WO2017213854A1 (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen

Publications (1)

Publication Number Publication Date
BR112018074299A2 true BR112018074299A2 (pt) 2019-03-12

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074299-6A BR112018074299A2 (pt) 2016-05-24 2017-05-24 composições farmacêuticas compreendendo eteplirsen

Country Status (15)

Country Link
US (1) US20190275072A1 (pt)
EP (1) EP3463390A1 (pt)
JP (1) JP2019516730A (pt)
KR (1) KR20190009343A (pt)
CN (1) CN109562123A (pt)
AU (1) AU2017278699A1 (pt)
BR (1) BR112018074299A2 (pt)
CA (1) CA3024178A1 (pt)
CO (1) CO2018013828A2 (pt)
IL (1) IL263040A (pt)
MA (1) MA45158A (pt)
MX (1) MX2018014129A (pt)
SG (1) SG11201809494VA (pt)
TW (1) TW201805002A (pt)
WO (1) WO2017213854A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP2021526796A (ja) * 2018-06-13 2021-10-11 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー
EP4219717A3 (en) * 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
WO2019241470A2 (en) * 2018-06-14 2019-12-19 Sarepta Therapeutics, Inc. Exon skipping oligomers and oligomer conjugates for muscular dystrophy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
ATE81872T1 (de) 1985-03-15 1992-11-15 James Summerton Stereoregulare polynukleotiden bindende polymere.
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
DE68914843T2 (de) 1988-09-01 1994-11-10 Risoe Forskningscenter Peptid-synthese und fester träger zur verwendung dabei.
HUE028632T2 (en) 2004-06-28 2016-12-28 Univ Western Australia To skip an antisense oligonucleotide exon and use it for procedures
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
KR101617472B1 (ko) 2007-11-15 2016-05-02 사렙타 쎄러퓨틱스 인코퍼레이티드 모르폴리노 올리고머의 합성 방법
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
PT2623507T (pt) 2010-09-30 2016-12-23 Nippon Shinyaku Co Ltd Derivado de ácido morfolino-nucleico
JP6496549B2 (ja) 2011-11-30 2019-04-03 サレプタ セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
CN103933549A (zh) * 2013-01-17 2014-07-23 刘海俊 一种新的血管抑素滴眼剂及其制备方法
US9506058B2 (en) * 2013-03-15 2016-11-29 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
AU2017278699A1 (en) 2018-11-15
EP3463390A1 (en) 2019-04-10
SG11201809494VA (en) 2018-12-28
IL263040A (en) 2018-12-31
CO2018013828A2 (es) 2018-12-28
US20190275072A1 (en) 2019-09-12
CA3024178A1 (en) 2017-12-14
TW201805002A (zh) 2018-02-16
CN109562123A (zh) 2019-04-02
JP2019516730A (ja) 2019-06-20
WO2017213854A1 (en) 2017-12-14
KR20190009343A (ko) 2019-01-28
MX2018014129A (es) 2019-04-29
MA45158A (fr) 2019-04-10

Similar Documents

Publication Publication Date Title
MX2021009673A (es) Moduladores de ror-gamma.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112017023269A2 (pt) métodos para tratamento de câncer
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
SG10201902664RA (en) Combination therapy for treating cancer
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017010177A2 (pt) composição para tratamento de tecido
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
BR112018074299A2 (pt) composições farmacêuticas compreendendo eteplirsen
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
BR112018000217A2 (pt) sistemas de distribuição de nanopartículas aperfeiçoados
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B350 Update of information on the portal [chapter 15.35 patent gazette]